Iovance Biotherapeutics: Q1 Earnings Snapshot
Published Fri, 27 Dec 2024 09:26:55 GMT
SAN CARLOS, Calif. (AP) — SAN CARLOS, Calif. (AP) — Iovance Biotherapeutics Inc. (IOVA) on Tuesday reported a loss of $107.4 million in its first quarter.On a per-share basis, the San Carlos, California-based company said it had a loss of 50 cents.The results surpassed Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for a loss of 84 cents per share._____This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on IOVA at https://www.zacks.com/ap/IOVASourceLegalZoom: Q1 Earnings Snapshot
Published Fri, 27 Dec 2024 09:26:55 GMT
GLENDALE, Calif. (AP) — GLENDALE, Calif. (AP) — LegalZoom.com Inc. (LZ) on Tuesday reported a loss of $2.4 million in its first quarter.The Glendale, California-based company said it had a loss of 1 cent per share. Earnings, adjusted for one-time gains and costs, came to 7 cents per share.The results surpassed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for earnings of 6 cents per share.The online platform for legal services posted revenue of $165.9 million in the period, also topping Street forecasts. Five analysts surveyed by Zacks expected $155 million.For the current quarter ending in June, LegalZoom said it expects revenue in the range of $166 million to $168 million.The company expects full-year revenue in the range of $630 million to $650 million._____This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on LZ at h...Mets’ Scherzer misses start against Reds due to neck spasms
Published Fri, 27 Dec 2024 09:26:55 GMT
CINCINNATI (AP) — New York Mets pitcher Max Scherzer was scratched from his scheduled start against the Cincinnati Reds on Tuesday night due to neck spasms.Left-hander David Peterson was recalled from Triple-A Syracuse to start the opener of a three-game series.The start would have been Scherzer’s second since a 10-game suspension by Major League Baseball for violating the prohibition on foreign substances during an April 19 game at the Los Angeles Dodgers. The three-time Cy Young Award winner allowed six runs and eight hits over 3 1/3 innings at Detroit in his return on May 3, leaving the 38-year-old right-hander 2-2 with a 5.56 ERA in five starts this season.Scherzer was limited to two starts for the Washington Nationals between June 30 and Aug. 22, 2019, because of a mid-back strain and a rhomboid strain.Scherzer started feeling a problem after throwing a light bullpen on Sunday.“It started feeling barks, so I got some treatment during the game,” he said Tuesday. “When I wo...VTEX: Q1 Earnings Snapshot
Published Fri, 27 Dec 2024 09:26:55 GMT
LONDON (AP) — LONDON (AP) — VTEX (VTEX) on Tuesday reported a loss of $7.3 million in its first quarter.The London-based company said it had a loss of 4 cents per share.The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 1 cent per share.The company that helps retailers build e-commerce businesses posted revenue of $42.3 million in the period, topping Street forecasts. Four analysts surveyed by Zacks expected $41.2 million.For the current quarter ending in June, VTEX said it expects revenue in the range of $45 million to $45.8 million.The company expects full-year revenue in the range of $185 million to $190 million._____This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on VTEX at https://www.zacks.com/ap/VTEXSourceWynn: Q1 Earnings Snapshot
Published Fri, 27 Dec 2024 09:26:55 GMT
LAS VEGAS (AP) — LAS VEGAS (AP) — Wynn Resorts Ltd. (WYNN) on Tuesday reported first-quarter net income of $12.3 million.The Las Vegas-based company said it had net income of 2 cents per share. Earnings, adjusted for non-recurring costs, came to 29 cents per share.The results surpassed Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for a loss of 18 cents per share.The casino operator posted revenue of $1.42 billion in the period, which also beat Street forecasts. Six analysts surveyed by Zacks expected $1.25 billion._____This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on WYNN at https://www.zacks.com/ap/WYNNSourceHow major US stock indexes fared Tuesday 5/9/2023
Published Fri, 27 Dec 2024 09:26:55 GMT
Wall Street edged lower following some mixed earnings reports, as stocks remain roughly where they’ve been stuck for more than a month. The S&P 500 fell 0.5% Tuesday, and the Dow Jones Industrial Average lost 56 points, or 0.2%. The Nasdaq fell 0.6%. The next big milestone for the market will be Wednesday’s report on inflation, which has come down but remains high. It could dictate the Federal Reserve’s next move on interest rates. Political leaders are also meeting in Washington Tuesday to try to avoid a default on the U.S. government’s debt.On Tuesday:The S&P 500 fell 18.95 points, or 0.5%, to 4,119.17.The Dow Jones Industrial Average fell 56.88 points, or 0.2%, to 33,561.81.The Nasdaq composite fell 77.36 points, or 0.6% to 12,179.55.The Russell 2000 index of smaller companies fell 4.79 points, or 0.3%, to 1,749.68.For the week:The S&P 500 is down 17.08 points, or 0.4%.The Dow is down 112.57 points, or 0.3%.The Nasdaq is down 55.86 points, or 0.5%.The Russell 2000 is ...MacroGenics: Q1 Earnings Snapshot
Published Fri, 27 Dec 2024 09:26:55 GMT
ROCKVILLE, Md. (AP) — ROCKVILLE, Md. (AP) — MacroGenics Inc. (MGNX) on Tuesday reported a loss of $38 million in its first quarter.On a per-share basis, the Rockville, Maryland-based company said it had a loss of 61 cents.The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of $1.07 per share.The biopharmaceutical company posted revenue of $24.5 million in the period, also missing Street forecasts. Three analysts surveyed by Zacks expected $129.7 million._____This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on MGNX at https://www.zacks.com/ap/MGNXSourceSimilar Genomics Systems: Q1 Earnings Snapshot
Published Fri, 27 Dec 2024 09:26:55 GMT
SAN DIEGO (AP) — SAN DIEGO (AP) — Singular Genomics Systems Inc. (OMIC) on Tuesday reported a loss of $23.6 million in its first quarter.On a per-share basis, the San Diego-based company said it had a loss of 33 cents.The life science technology company posted revenue of $863,000 in the period._____This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on OMIC at https://www.zacks.com/ap/OMICSourceHalozyme Therapeutics: Q1 Earnings Snapshot
Published Fri, 27 Dec 2024 09:26:55 GMT
SAN DIEGO (AP) — SAN DIEGO (AP) — Halozyme Therapeutics Inc. (HALO) on Tuesday reported first-quarter profit of $39.6 million.The San Diego-based company said it had net income of 29 cents per share. Earnings, adjusted for one-time gains and costs, came to 47 cents per share.The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for earnings of 48 cents per share.The biopharmaceutical company posted revenue of $162.1 million in the period, also missing Street forecasts. Five analysts surveyed by Zacks expected $174.2 million.Halozyme Therapeutics expects full-year earnings in the range of $2.50 to $2.65 per share, with revenue in the range of $815 million to $845 million._____This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on HALO at https://www.zacks.com/ap/HALOSourceMannKind: Q1 Earnings Snapshot
Published Fri, 27 Dec 2024 09:26:55 GMT
DANBURY, Conn. (AP) — DANBURY, Conn. (AP) — MannKind Corp. (MNKD) on Tuesday reported a loss of $9.8 million in its first quarter.The Danbury, Connecticut-based company said it had a loss of 4 cents per share.The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 5 cents per share.The biopharmaceutical company posted revenue of $40.6 million in the period, also topping Street forecasts. Three analysts surveyed by Zacks expected $37.4 million._____This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on MNKD at https://www.zacks.com/ap/MNKDSourceLatest news
- US Navy plane overshoots runway, ends up in Hawaii bay
- 25 years: Local non-profit is national model for tackling homelessness
- Shorthanded Texas falls in Empire Classic title game to No. 5 UConn 81-71
- Jaden McDaniels leaves Monday’s game with ankle injury
- River City Casino hosts Guns ‘N Hoses weigh-in
- Gov. Jared Polis signs four bills, including property tax relief, after lawmakers wrap up special session
- Nikola Jokic, Michael Malone ejected but Nuggets hang on to hand Pistons 12th consecutive loss
- Howell, Wilson reach milestones while leading defensive resurgence for Colorado State
- Video shows fatal CHP shooting on 105 Freeway; state investigating
- Crush of Thanksgiving traffic underway in SoCal